Visual Rating and Computer-Assisted Analysis of FDG PET in the Prediction of Conversion to Alzheimer’s Disease in Mild Cognitive Impairment
Fluorodeoxyglucose (FDG) positron emission tomography (PET) is useful to predict Alzheimer’s disease (AD) conversion in patients with mild cognitive impairment (MCI). However, few studies have examined the extent to which FDG PET alone can predict AD conversion and compared the efficacy between visual and computer-assisted analysis directly.
The current study aimed to evaluate the value of FDG PET in predicting the conversion to AD in patients with MCI and to compare the predictive values of visual reading and computer-assisted analysis.
Methods and materials
A total of 54 patients with MCI were evaluated with FDG PET and followed-up for 2 years with final diagnostic evaluation. FDG PET images were evaluated by (1) traditional visual rating, (2) composite score of visual rating of the brain cortices, and (3) composite score of computer-assisted analysis. Receiver operating characteristics (ROC) curves were compared to analyze predictive values.
Nineteen patients (35.2%) converted to AD from MCI. The area under the curve (AUC) of the ROC curve of the traditional visual rating, composite score of visual rating, and computer-assisted analysis were 0.67, 0.76, and 0.79, respectively. ROC curves of the composite scores of the visual rating and computer-assisted analysis were comparable (Z = 0.463, p = 0.643).
Visual rating and computer-assisted analysis of FDG PET scans were analogously accurate in predicting AD conversion in patients with MCI. Therefore, FDG PET may be a useful tool for screening AD conversion in patients with MCI, when using composite score, regardless of the method of interpretation.
JMK, JYL, YKK, and DYL designed the study. JYL, BKS, MSB, and DYL acquired the data, and JMK, JYL, JEC, SKS, HJI, JHL, and YHR analyzed and interpreted the results of experiments. JMK wrote the main manuscript and prepared figures. JMK, JYL, BKS, and YKK edited and revised the manuscript. All authors reviewed and approved the manuscript.
Compliance with Ethical Standards
Conflict of interest
All authors (JMK, JYL, YKK, BKS, MSB, JEC, SKS, HJI, JHL, YHR, and DYL) declare that they have no conflict of interest.
This study was supported by the National Evidence-based Healthcare Collaborating Agency (NECA-C-13-010) and by a grant from Ministry of Science, ICT and Future Planning (grant no. NRF-2014M3C7A1046042). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Written informed consents were obtained from all individual participants included in the study.
- 7.Mielke R, Heiss W-D. Positron emission tomography for diagnosis of Alzheimer’s disease and vascular dementia. New York: Springer; 1998.Google Scholar
- 10.Silverman DH. Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. J Nuc Med. 2004;45(4):594–607.Google Scholar
- 12.Mosconi L, Silverman DH. FDG PET in the evaluation of mild cognitive impairment and early dementia. PET in the evaluation of Alzheimer’s disease and related disorders. New York: Springer; 2009. p. 49–65.Google Scholar
- 14.Chen K, Langbaum JB, Fleisher AS, Ayutyanont N, Reschke C, Lee W, et al. Twelve-month metabolic declines in probable Alzheimer’s disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: findings from the Alzheimer’s Disease Neuroimaging Initiative. Neuroimage. 2010;51(2):654–64.CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Yuan Y, Gu Z-X, Wei W-S. Fluorodeoxyglucose–positron-emission tomography, single-photon emission tomography, and structural MR imaging for prediction of rapid conversion to Alzheimer disease in patients with mild cognitive impairment: a meta-analysis. Am J Neuroradiol. 2009;30(2):404–10.CrossRefPubMedGoogle Scholar
- 17.Smailagic N, Vacante M, Hyde C, Martin S, Ukoumunne O, Sachpekidis C. 18F-FDG PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2015. https://doi.org/10.1002/14651858.CD010632.pub2.Google Scholar
- 18.Young J, Modat M, Cardoso MJ, Mendelson A, Cash D, Ourselin S. Accurate multimodal probabilistic prediction of conversion to Alzheimer’s disease in patients with mild cognitive impairment. NeuroImage Clin. 2013;2:735–45. https://doi.org/10.1016/j.nicl.2013.05.004.CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Shaffer JL, Petrella JR, Sheldon FC, Choudhury KR, Calhoun VD, Coleman RE, et al. Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers. Radiology. 2013;266(2):583–91. https://doi.org/10.1148/radiol.12120010.CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Anchisi D, Borroni B, Franceschi M, Kerrouche N, Kalbe E, Beuthien-Beumann B, et al. Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch Neurol. 2005;62(11):1728–33. https://doi.org/10.1001/archneur.62.11.1728.CrossRefPubMedGoogle Scholar
- 23.Lee JH, Lee KU, Lee DY, Kim KW, Jhoo JH, Kim JH, et al. Development of the Korean version of the Consortium to Establish a Registry for Alzheimer’s Disease Assessment Packet (CERAD-K) clinical and neuropsychological assessment batteries. J Gerontol B Psychol Sci Soc Sci. 2002;57(1):P47–53.CrossRefPubMedGoogle Scholar
- 25.Shon JM, Lee DY, Seo EH, Sohn BK, Kim JW, Park SY et al. Functional neuroanatomical correlates of the executive clock drawing task (CLOX) performance in Alzheimer’s disease: a FDG-PET study. Neuroscience. 2013;246(Supplement C):271–80. https://doi.org/10.1016/j.neuroscience.2013.05.008.
- 27.Morbelli S, Brugnolo A, Bossert I, Buschiazzo A, Frisoni GB, Galluzzi S, et al. Visual versus semi-quantitative analysis of 18F-FDG-PET in amnestic MCI: an European Alzheimer’s Disease Consortium (EADC) project. J Alzheimers Dis. 2015;44(3):815–26. https://doi.org/10.3233/jad-142229.CrossRefPubMedGoogle Scholar
- 31.Laforce R Jr, Buteau JP, Paquet N, Verret L, Houde M, Bouchard RW. The value of PET in mild cognitive impairment, typical and atypical/unclear dementias: a retrospective memory clinic study. Am J Alzheimers Dis Other Demen. 2010;25(4):324–32. https://doi.org/10.1177/1533317510363468.CrossRefPubMedGoogle Scholar
- 32.Arbizu J, Prieto E, Martinez-Lage P, Marti-Climent JM, Garcia-Granero M, Lamet I, et al. Automated analysis of FDG PET as a tool for single-subject probabilistic prediction and detection of Alzheimer’s disease dementia. Eur J Nucl Med Mol Imaging. 2013;40(9):1394–405. https://doi.org/10.1007/s00259-013-2458-z.CrossRefPubMedGoogle Scholar
- 33.Zhang S, Han D, Tan X, Feng J, Guo Y, Ding Y. Diagnostic accuracy of 18 F-FDG and 11 C-PIB-PET for prediction of short-term conversion to Alzheimer’s disease in subjects with mild cognitive impairment. Int J Clin Pract. 2012;66(2):185–98. https://doi.org/10.1111/j.1742-1241.2011.02845.x.CrossRefPubMedGoogle Scholar
- 34.Pagani M, De Carli F, Morbelli S, Oberg J, Chincarini A, Frisoni GB et al. Volume of interest-based [18F]fluorodeoxyglucose PET discriminates MCI converting to Alzheimer’s disease from healthy controls. A European Alzheimer’s Disease Consortium (EADC) study. Neuroimage Clin. 2015;7:34–42. https://doi.org/10.1016/j.nicl.2014.11.007.